查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2002995

獸用疼痛管理市場：依動物種類、產品類型、給藥途徑、最終用戶及通路分類－2026-2032年全球市場預測

Veterinary Pain Management Market by Animal Type, Product Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物疼痛管理市場價值將達到 22.5 億美元，到 2026 年將成長到 24.5 億美元，到 2032 年將達到 44.7 億美元，年複合成長率為 10.28%。

主要市場統計數據
基準年 2025 22.5億美元
預計年份：2026年 24.5億美元
預測年份：2032年 44.7億美元
複合年成長率 (%) 10.28%

一個全面的臨床和商業性趨勢框架，重新定義了動物疼痛管理的實踐，無論物種或護理環境如何。

隨著臨床醫生、生產商和經銷商積極應對不斷變化的動物健康重點、法律規範和客戶期望，獸醫疼痛管理領域正經歷快速變革。藥理學的進步、多方面鎮痛的興起以及人們對動物福利日益成長的關注，正在重塑伴侶動物、馬匹和生產動物的治療通訊協定。同時，科技驅動的診斷和數位治療方法也開始影響疼痛的評估和管理方式，為整合到整個臨床工作流程中創造了新的機會。

藥理學、給藥方法和分銷管道的創新如何共同重塑獸醫鎮痛的臨床通訊協定和商業策略？

在科學創新、監管改革和相關人員期望變化的推動下，獸醫鎮痛領域正經歷著一場變革。非類固醇消炎劑的進步、局部麻醉劑製劑的改進以及對鴉片類藥物合理使用的重新關注，正在改變臨床實踐中的治療流程。同時，給藥途徑的進步，例如長效注射劑和經皮製劑，能夠延長鎮痛持續時間並遵守用藥，尤其是在門診和居家照護環境中。

評估美國在 2025 年宣布或實施的關稅措施對供應鏈、採購和臨床連續性的連鎖影響。

美國計劃於2025年加徵關稅，將對動物疼痛管理領域的相關人員產生多方面的影響，包括供應鏈、採購成本和策略採購決策。依賴全球生產網路採購活性成分、輔料或成品製劑的製造商可能面臨更高的收貨成本和更長的前置作業時間，迫使他們重新考慮供應商多元化和近岸外包方案。對於契約製造和經銷商，進口關稅的增加可能會壓縮利潤空間，促使他們提高營運效率並與分銷通路合作夥伴重新談判貿易條款。

各細分市場的策略挑戰：動物類型、治療領域、給藥途徑、最終用戶和分銷管道的選擇如何影響臨床引入和商業性定位。

透過市場區隔獲得的洞見揭示了不同動物類型、產品類別、給藥途徑、最終用戶和分銷管道在臨床和商業性行為方面的差異。按動物類型（貓、狗、馬、牲畜）分析表明，由於物種特異性的動態、給藥複雜性和客戶期望，鎮痛藥的使用模式存在差異，從而推動了差異化的產品開發和標籤策略。產品類型細分揭示了局部麻醉劑、非類固醇消炎劑 ( NSAIDs) 和鴉片類藥物之間的差異，導致監管審查等級、合理使用注意事項和臨床適應症各不相同。 NSAIDs非類固醇消炎劑還可根據特定藥物進一步細分，例如卡洛芬、氟尼辛、美洛昔康和羅貝考昔，每種藥物都具有其獨特的安全性特徵和獸醫製劑傾向。

美洲、歐洲、中東、非洲和亞太地區的法規、臨床實踐和分銷方面的區域細微差別會影響准入和商業化策略。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢差異顯著，每個地區都有獨特的法規結構、臨床實踐模式和供應鏈結構，這些都會影響產品的取得和商業化。在美洲，雖然獸醫院的整合和數位化採購的日益普及提高了效率，但人們對服務包裝和培訓支援的期望也越來越高。監管管道往往專注於已建立的藥物安全監測系統，這些系統指南上市後監測策略。

製藥公司和專業動物用藥品公司之間的競爭和策略行動，透過專注於證據、服務和分銷管道來實現差異化。

獸用疼痛管理領域的競爭格局呈現出多元化的特點，既有成熟的製藥公司，也有專注於動物用藥品研發的專業公司，還有不斷開發新配方和給藥系統的創新企業。主要企業優先考慮建立可靠的臨床證據、進行針對獸醫專業人士的精準宣傳活動，並加大對產品安全監測的投入，以實現產品差異化。為了尋求配方科學、分銷網路或區域監管方面的專業知識等互補能力，戰略聯盟和許可合作十分普遍。

為製造商和經銷商提供切實可行的策略措施，以增強供應韌性，加快臨床醫生採用，並最佳化跨通路的商業性方法。

產業領導企業應推動一系列切實可行的舉措，以增強市場韌性，加速差異化治療方法的推廣應用，並使商業模式適應不斷變化的臨床環境。首先，製造商和經銷商需要實施全面的價值鏈映射和雙源採購策略，以減輕關稅波動和原料短缺的影響。其次，投資於獸醫專業人員和飼主的多面向鎮痛教育，將有助於循證處方箋，並透過改善可證實的治療效果和提高遵守用藥來提升產品價值。

採用嚴謹的混合方法研究途徑，結合專家訪談、臨床文獻整合和基於情境的供應鏈分析，可以獲得實用的見解。

本分析的調查方法結合了定性專家訪談、系統性文獻綜述以及監管指南和臨床實踐資源，以確保從所有相關人員的角度出發，獲得平衡的觀點。主要資訊來源包括與執業獸醫、藥理學家、監管專家和分銷主管進行的結構化討論，以了解實際決策因素、治療偏好和採購實踐。次要資訊來源包括同行評審的臨床研究、藥理學教科書和公開的監管文件，檢驗關鍵鎮痛藥及其給藥途徑的安全性、給藥注意事項和標籤說明。

整合協調臨床創新、監管期望和商業性韌性的策略重點，將改善動物疼痛管理和組織績效。

總之，動物疼痛管理領域正處於一個轉折點，臨床創新、不斷變化的經銷管道和宏觀經濟壓力相互交織，重新定義了機會和風險。積極整合供應鏈韌性、投資於臨床醫生教育並根據物種和環境特定需求量身定做產品和管道策略的相關人員，將更有利於改善患者療效並確保商業性競爭力。考慮到監管預期、給藥途徑偏好和終端用戶採購行為之間的相互作用，需要製定一項協調一致的策略，將臨床證據與切實可行的打入市場策略相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：獸醫疼痛管理市場：依動物類型分類

  • 貓
  • 狗
  • 馬
  • 家畜

第9章：獸醫疼痛管理市場：依產品類型分類

  • 局部麻醉劑
  • 非類固醇消炎劑
    • 卡洛芬
    • 氟尼辛
    • 美洛昔康
    • 羅貝那昔布
  • 鴉片類藥物

第10章：獸醫疼痛管理市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
  • 外用
    • 凝膠
    • 修補
    • 噴
  • 經皮

第11章：獸醫疼痛管理市場：依最終用戶分類

  • 網路藥房
  • 研究機構
  • 零售藥房
  • 動物診所
  • 動物醫院

第12章：獸醫疼痛管理市場：依通路分類

  • 直銷
  • 獸醫院藥房
  • 網路藥房
  • 零售藥房

第13章 動物疼痛管理市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：獸醫疼痛管理市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：獸醫疼痛管理市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國獸醫疼痛管理市場

第17章：中國獸用疼痛管理市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-957C47F93EAD

The Veterinary Pain Management Market was valued at USD 2.25 billion in 2025 and is projected to grow to USD 2.45 billion in 2026, with a CAGR of 10.28%, reaching USD 4.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.25 billion
Estimated Year [2026] USD 2.45 billion
Forecast Year [2032] USD 4.47 billion
CAGR (%) 10.28%

Comprehensive framing of clinical and commercial dynamics redefining veterinary pain management practices across species and care settings

The veterinary pain management landscape is undergoing rapid transformation as clinicians, manufacturers, and distributors respond to evolving animal health priorities, regulatory frameworks, and client expectations. Advances in pharmacology, a shift toward multimodal analgesia, and heightened attention to animal welfare are reshaping protocols across companion, equine, and production animal practice. At the same time, technology-enabled diagnostics and digital therapeutics are beginning to influence how pain is assessed and managed, creating new opportunities for integration across clinical workflows.

Decision-makers must understand not only product-level innovations but also changes in delivery modalities, administration preferences, and end-user procurement pathways. This report synthesizes clinical, commercial, and distributional dynamics to provide a consolidated view of current practice and emergent pressures. By focusing on treatment modalities, administration routes, and practitioner adoption behaviors, the analysis highlights actionable implications for product development, regulatory engagement, and commercial strategy. Transitional context links clinical need to market opportunity and frames the strategic considerations that follow.

How innovations in pharmacology, delivery methods, and distribution channels are jointly reshaping clinical protocols and commercial strategies in veterinary analgesia

The landscape for veterinary analgesia is experiencing transformative shifts driven by scientific innovation, regulatory recalibration, and changing stakeholder expectations. Advances in nonsteroidal anti-inflammatory agents, refinement of local anesthetic formulations, and renewed attention to opioid stewardship are altering therapeutic algorithms in clinical practice. Concurrently, progress in routes of administration-such as long-acting injectables and transdermal delivery systems-enables extended analgesic coverage and improved compliance, particularly in outpatient or home-care environments.

On the commercial side, distribution channels are fragmenting as digital pharmacies and direct-to-consumer models gain traction, prompting manufacturers to reassess channel strategies and patient support services. Veterinary clinics and hospitals are evolving into more sophisticated care hubs that demand integrated product support, training, and evidence-based protocols. These converging forces are incentivizing cross-disciplinary collaborations among pharmacologists, device developers, and veterinary practitioners to co-develop solutions that meet rising standards for efficacy, safety, and animal welfare, thereby reshaping competitive dynamics and go-to-market approaches.

Evaluating the cascading supply chain, procurement, and clinical continuity effects stemming from United States tariff measures announced or implemented in 2025

The prospect of tariffs introduced by the United States in 2025 carries multifaceted implications for veterinary pain management stakeholders, affecting supply chains, procurement costs, and strategic sourcing decisions. Manufacturers that rely on global manufacturing networks for active pharmaceutical ingredients, excipients, or finished formulations may face higher landed costs and disrupted lead times, prompting a reassessment of supplier diversification and nearshoring options. For contract manufacturers and distributors, greater import duties can compress margins and incentivize operational efficiencies or renegotiated commercial terms with channel partners.

Clinics and hospitals that procure proprietary or specialized formulations may experience procurement friction as distributors pass through cost increases or adjust inventory policies. In response, buyers could pursue longer-term purchase agreements, seek alternative generics, or increase onshore stockpiling to mitigate short-term volatility. Additionally, regulatory compliance, customs processing, and documentation burdens could introduce administrative overheads that slow product introductions. Collectively, these dynamics underscore the importance of scenario planning, supply chain mapping, and proactive engagement with logistics partners to preserve continuity of care and maintain access to critical analgesic therapies.

Segment-driven strategic imperatives showing how species, therapeutic class, administration route, end user, and distribution choices shape clinical adoption and commercial positioning

Insights derived from segmentation illuminate distinct clinical and commercial behaviors across animal type, product class, administration route, end user, and distribution pathways. When analyzed by animal type-cats, dogs, equine, and livestock-adoption patterns for analgesic classes diverge due to species-specific pharmacodynamics, dosing complexity, and client expectations, driving differentiated product development and labeling strategies. Within product type segmentation, distinctions among local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids reveal varying regulatory scrutiny, stewardship considerations, and clinical indications; the nonsteroidal anti-inflammatory category further differentiates around agents such as carprofen, flunixin, meloxicam, and robenacoxib, each associated with unique safety profiles and veterinary prescribing preferences.

Route of administration segmentation-injectable, oral, topical, and transdermal-highlights user-centric trade-offs between onset, duration, and ease of administration; injectable options subdivide into intramuscular, intravenous, and subcutaneous approaches tailored to care setting and patient tolerance, while topical applications encompass gels, patches, and sprays that support at-home management or localized therapy. End user segmentation captures how online pharmacies, research institutes, retail pharmacies, veterinary clinics, and veterinary hospitals impose different procurement cycles, compliance requirements, and service expectations that shape commercial engagement. Finally, distribution channel segmentation-direct distribution, hospital pharmacies, online pharmacies, and retail pharmacies-illustrates how route-to-market choices influence pricing, promotional focus, and product support investments, underscoring the need for channel-specific value propositions and partnership models.

Regional regulatory, clinical practice, and distribution nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence access and commercialization strategies

Regional dynamics vary substantially across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct regulatory frameworks, clinical practice patterns, and supply chain architectures that influence product access and commercialization. In the Americas, practice consolidation among clinics and increasing use of digital procurement create efficiencies but also raise expectations for bundled service offerings and training support; regulatory pathways tend to favor well-established pharmacovigilance systems, which informs post-market surveillance strategies.

Across Europe, the Middle East & Africa, regulatory heterogeneity and divergent reimbursement models require tailored regulatory and market access approaches, while growing investments in veterinary education and welfare standards are driving demand for evidence-based analgesic protocols. The Asia-Pacific region exhibits rapid infrastructure development, expanding veterinary service networks, and variable local manufacturing capacity, which together incentivize partnerships with regional distributors and investments in localized supply chain resilience. Navigating these regional nuances calls for adaptive regulatory strategy, culturally attuned marketing, and distribution models that reconcile global product standards with local market realities.

Competitive dynamics and strategic behaviours among pharmaceutical and specialty animal health companies shaping differentiation through evidence, services, and channel focus

The competitive landscape in veterinary pain management is characterized by a mix of established pharmaceutical manufacturers, specialty animal health companies, and agile innovators developing new formulations and delivery systems. Leading organizations prioritize robust clinical evidence generation, targeted educational outreach to veterinary professionals, and investments in product safety monitoring to differentiate their offerings. Strategic collaborations and licensing agreements are common as companies seek complementary capabilities in formulation science, distribution networks, or regional regulatory expertise.

Product differentiation increasingly depends on demonstrating superior tolerability, simplified dosing regimens, or clear advantages in real-world settings, while companies that offer integrated support services-such as training modules, dosing calculators, and client education materials-achieve deeper clinical engagement. Competitive positioning also reflects decisions about channel focus; some companies emphasize partnerships with hospital pharmacies and veterinary hospitals for high-touch engagement, whereas others optimize for retail and online pharmacy distribution to capture convenience-driven end users. These dynamics create openings for specialized entrants to capture niche segments while larger firms consolidate presence through portfolio breadth and service depth.

Actionable strategic measures for manufacturers and distributors to fortify supply resilience, accelerate clinician adoption, and optimize channel-specific commercial approaches

Industry leaders should pursue a set of pragmatic actions that strengthen resilience, accelerate adoption of differentiated therapies, and align commercial models with evolving clinical practice. First, manufacturers and distributors need to execute comprehensive supply chain mapping and dual-sourcing strategies to reduce exposure to tariff-driven disruptions and raw material shortages. Second, investing in multimodal analgesia education for veterinary professionals and clients will support evidence-based prescribing and enhance product value through demonstrable outcomes and adherence improvements.

Third, prioritizing development of user-centric administration formats-such as long-acting injectables or transdermal patches-can address adherence challenges and improve patient welfare across species. Fourth, companies must tailor channel strategies to meet the distinct needs of veterinary clinics, hospitals, retail pharmacies, and online platforms, offering differentiated commercial incentives and service bundles. Finally, proactive regulatory engagement and robust post-market surveillance will mitigate safety concerns and support faster market acceptance; collectively, these measures will enable organizations to respond to competitive pressures while delivering measurable benefits to clinicians and animal owners.

Rigorous mixed-method research approach combining expert interviews, clinical literature synthesis, and scenario-based supply chain analysis to produce actionable insights

The research methodology underpinning this analysis integrates qualitative expert interviews, systematic literature review, and synthesis of regulatory guidance and clinical practice resources to ensure balanced perspectives across stakeholders. Primary inputs included structured consultations with practicing veterinarians, pharmacologists, regulatory specialists, and distribution executives to capture real-world decision drivers, therapeutic preferences, and procurement practices. Secondary inputs relied on peer-reviewed clinical studies, pharmacology texts, and public regulatory documentation to validate safety profiles, administration considerations, and labeling implications for key analgesic agents and delivery platforms.

Analytical approaches combined cross-segmentation mapping with scenario-based supply chain stress testing to evaluate vulnerabilities and response options. Triangulation between primary interviews and secondary sources was applied to reduce bias and enhance the robustness of thematic conclusions. Where appropriate, sensitivity analyses were used to examine the implications of tariff-induced cost pressures, channel shifts, and adoption of new administration modalities. This mixed-method framework supports actionable insights while preserving methodological transparency and reproducibility.

Synthesis of strategic priorities that reconcile clinical innovation, regulatory expectations, and commercial resilience to advance veterinary pain care and organizational performance

In conclusion, the veterinary pain management sector is at an inflection point where clinical innovation, distribution evolution, and macroeconomic pressures converge to redefine opportunity and risk. Stakeholders that proactively integrate supply chain resilience, invest in clinician education, and tailor product and channel strategies to species- and setting-specific needs will be best positioned to deliver improved patient outcomes and secure commercial advantage. The interplay between regulatory expectations, administration route preferences, and end-user procurement behaviors demands coordinated strategies that align clinical evidence with pragmatic go-to-market tactics.

As markets continue to evolve, organizations should prioritize adaptive planning, collaborative partnerships, and sustained investment in post-market evidence generation to support long-term acceptance and trust. By focusing on these strategic pillars, companies and care providers can navigate near-term disruptions while advancing toward higher standards of pain management across companion, equine, and livestock populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Pain Management Market, by Animal Type

  • 8.1. Cats
  • 8.2. Dogs
  • 8.3. Equine
  • 8.4. Livestock

9. Veterinary Pain Management Market, by Product Type

  • 9.1. Local Anesthetics
  • 9.2. Nonsteroidal Anti-Inflammatory Drugs
    • 9.2.1. Carprofen
    • 9.2.2. Flunixin
    • 9.2.3. Meloxicam
    • 9.2.4. Robenacoxib
  • 9.3. Opioids

10. Veterinary Pain Management Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Oral
  • 10.3. Topical
    • 10.3.1. Gels
    • 10.3.2. Patches
    • 10.3.3. Sprays
  • 10.4. Transdermal

11. Veterinary Pain Management Market, by End User

  • 11.1. Online Pharmacies
  • 11.2. Research Institutes
  • 11.3. Retail Pharmacies
  • 11.4. Veterinary Clinics
  • 11.5. Veterinary Hospitals

12. Veterinary Pain Management Market, by Distribution Channel

  • 12.1. Direct Distribution
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Veterinary Pain Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Pain Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Pain Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Pain Management Market

17. China Veterinary Pain Management Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Boehringer Ingelheim International GmbH
  • 18.6. Ceva Sante Animale S.A.
  • 18.7. Dechra Pharmaceuticals PLC
  • 18.8. Elanco Animal Health Incorporated
  • 18.9. Merck & Co., Inc.
  • 18.10. Norbrook Laboratories Limited
  • 18.11. Phibro Animal Health Corporation
  • 18.12. Vetoquinol S.A.
  • 18.13. Virbac S.A.
  • 18.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY FLUNIXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY FLUNIXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY FLUNIXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROBENACOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROBENACOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROBENACOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DIRECT DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DIRECT DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 226. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA VETERINARY PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)